Document is current
Any future updates will be listed below
-
Authors
Arcos-Burgos, Mauricio
Vélez, Jorge I. https://orcid.org/0000-0002-3146-7899
Martinez, Ariel F. https://orcid.org/0000-0002-4109-1928
Ribasés, Marta https://orcid.org/0000-0003-1039-1116
Ramos-Quiroga, Josep A.
Sánchez-Mora, Cristina
Richarte, Vanesa
Roncero, Carlos https://orcid.org/0000-0003-1421-7385
Cormand, Bru https://orcid.org/0000-0001-5318-4382
Fernández-Castillo, Noelia
Casas, Miguel
Lopera, Francisco
Pineda, David A.
Palacio, Juan D.
Acosta-López, Johan E.
Cervantes-Henriquez, Martha L.
Sánchez-Rojas, Manuel G.
Puentes-Rozo, Pedro J.
Molina, Brooke S. G.
,
Boden, Margaret T.
Wallis, Deeann
Lidbury, Brett
Newman, Saul https://orcid.org/0000-0001-9841-1518
Easteal, Simon https://orcid.org/0000-0002-0462-502X
Swanson, James
Patel, Hardip
Volkow, Nora https://orcid.org/0000-0001-6668-0908
Acosta, Maria T.
Castellanos, Francisco X. https://orcid.org/0000-0001-9192-9437
de Leon, Jose https://orcid.org/0000-0002-7756-2314
Mastronardi, Claudio A.
Muenke, Maximilian
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (DA039881)
University of California Berkeley
Duke | School of Medicine, Duke University
NYU | School of Medicine, New York University
McGill University
Columbia University
University of Pittsburgh
UofI | University of Illinois at Chicago
Stanford University
Office of Special Education Programs, Office of Special Education and Rehabilitative Services
United States Department of Justice | OJP | Office of Juvenile Justice and Delinquency Prevention
Eli Lilly and Company
National Alliance for Research on Schizophrenia and Depression
University of Kentucky
- License Information
-
More Information
Article History
Received: 15 February 2017
Revised: 18 December 2018
Accepted: 2 January 2019
First Online: 29 January 2019
Conflict of interest
: J.A.R.-Q has served on the speakers’ bureau and acted as consultant for Eli Lilly and Co., Janssen-Cilag, Novartis, Lundbeck, Shire, Ferrer, and Laboratorios Rubió. He has received travel awards from Eli Lilly and Co., Janssen-Cilag, and Shire for participating in psychiatric meetings. The ADHD Program chaired by J.A.R.-Q. has received unrestricted educational and research support from Eli Lilly and Co., Janssen-Cilag, Shire, Rovi, Ferrer and Laboratorios Rubió in the past two years. The remaining authors declare that they have no conflict of interest.
